EGFR and cancer: Treatment of OvCAR3 ovarian cancer cells pretargeted with anti-EGFR-FITC with scFvFITC:sFasL resulted in dose-dependent induction of apoptosis with a corresponding loss in cancer cell viability (Fig. 4A and B).